Hypertension and Atrial Fibrillation: A Frontier Review From the AF-SCREEN International Collaboration.
Niiranen TJ. et al, (2025), Circulation, 151, 863 - 877
Benefits of aldosterone receptor antagonism in chronic kidney disease: the BARACK-D RCT.
Hobbs FDR. et al, (2025), Health Technol Assess, 29, 1 - 130
Stroke incidence in heart failure and atrial fibrillation: population cohort study.
Jones NR. et al, (2025), Br J Gen Pract
Assessment of frailty in patients with heart failure: A new Heart Failure Frailty Score developed by Delphi consensus
Vitale C. et al, (2025), ESC Heart Failure
A service evaluation of the implementation of a novel digital intervention for hypertension self-monitoring and management system in primary care (SHIP): protocol for a mixed methods study
Smith A. et al, (2024), BMC Cardiovascular Disorders, 24
COVID-19 and influenza vaccine uptake among pregnant women in national cohorts of England and Wales
Gu X. et al, (2024), npj Vaccines, 9
Risk of COVID-19 death in adults who received booster COVID-19 vaccinations in England
Ward IL. et al, (2024), Nature Communications, 15
Self-monitoring of blood pressure following a stroke or transient ischaemic attack (TASMIN5S): a randomised controlled trial
McManus RJ. et al, (2024), BMC Cardiovascular Disorders, 24
Validity and timeliness of cancer diagnosis data collected during a prospective cohort study and reported by the English and Welsh cancer registries: a retrospective, comparative analysis
Jackson A. et al, (2024), The Lancet Oncology, 25, 1476 - 1486
Prioritising primary care patients with unexpected weight loss for cancer investigation: diagnostic accuracy study (update)
Nicholson BD. et al, (2024), BMJ (Clinical research ed.), 387
Favipiravir for COVID-19 in adults in the community in PRINCIPLE, an open-label, randomised, controlled, adaptive platform trial of short- and longer-term outcomes
Hobbs FR. et al, (2024), Journal of Infection, 89
Effect of antihypertensive deprescribing on hospitalisation and mortality: long-term follow-up of the OPTiMISE randomised controlled trial
Sheppard JP. et al, (2024), The Lancet Healthy Longevity, 5, e563 - e573
Effect of antihypertensive deprescribing on serious adverse events, mortality, and cardiovascular disease: Long-term follow-up of the OPTiMISE randomised controlled trial
SHEPPARD J. et al, (2024), The Lancet Healthy Longevity
Reliability of single-lead electrocardiogram interpretation to detect atrial 1 fibrillation: insights from the SAFER Feasibility Study
MCMANUS R. and HOBBS R., (2024), Europace
A Profile of Influenza Vaccine Coverage for 2019-2020: Database Study of the English Primary Care Sentinel Cohort
Hoang U. et al, (2024), JMIR public health and surveillance, 10
EFFECT OF ANTIHYPERTENSIVE DEPRESCRIBING ON SERIOUS ADVERSE EVENTS, MORTALITY, AND CARDIOVASCULAR DISEASE: LONG-TERM FOLLOW-UP OF THE OPTIMISE RANDOMISED CONTROLLED TRIAL
Sheppard J. et al, (2024), Journal of Hypertension, 42, e109 - e110